PharmaSURVEYOR's Advanced Drug Safety Service Connects to Microsoft HealthVault
News Jun 12, 2009
PharmaSURVEYOR announced the integration of their Advanced Drug Safety service with Microsoft HealthVault at the Microsoft Connected Health Conference.
PharmaSURVEYOR offers a personalized drug assessment tool designed to show users not only drug-drug interactions but the much more common and often dangerous adverse drug side effects.
HealthVault users will be able to run a survey of medications stored in their HealthVault account and PharmaSURVEYOR users will be able to easily create a HealthVault account to store their medications.
"PharmaSURVEYOR is proud to join the growing ecosystem of services connected by HealthVault," said Erick Von Schweber, Executive Co-Chair of PharmaSURVEYOR.
"For example, a consumer can download a family member's medications to HealthVault from their pharmacy, run an Advanced Drug Safety survey of those medications and search for any symptoms they're having in PharmaSURVEYOR. Their safety survey will reveal which of their symptoms may actually be side effects, the medications that are more likely causing these and possible substitute drugs that can reduce their risk. The Advanced Drug Safety survey can be used in collaboration with their doctor to identify and diagnose those problems and get them resolved."
"Drug interaction checkers only flag interaction problems, not combined risks, and they don't help to resolve any problems; PharmaSURVEYOR does!" said Mr. Von Schweber. "PharmaSURVEYOR enables the HealthVault user to perform 'what-if' analyses, like using a spreadsheet, to simulate and evaluate the safety impact of changes to their drug regimen. There's nothing else like it."
Watch: Could Digital Microfluidics Revolutionise Experimentation?News
Technology using 'programmable droplets' could enable automated research on a grand scale.READ MORE
New Research Could Significantly Accelerate Drug DiscoveryNews
Scientists have developed a suite of computer programs that cull through data on structure and genomic sequencing to identify the features that distinguish one enzyme from similar enzymes. This research has the potential to significantly accelerate drug discovery, allowing scientists to develop more effective drugs, more quickly.READ MORE
New Partnership to Provide Bioanalytical and DMPK ServicesNews
Concept Life Sciences, the integrated drug discovery, development and analytical services company, and Alderley Analytical, bioanalytical Contract Research Organisation (CRO), today announced they have signed a partnership agreement to provide high-value bioanalytical and DMPK study services.